Alumis posts narrower Q3 loss as NDA nears, but a lupus miss narrows envudeucitinib's path
Lower R&D cut the quarterly net loss to $94.9M, with a psoriasis NDA still due in 4Q 2026 and cash guided into 4Q 2027, while the LUMUS Phase 2b missed in the overall population.
The quarter in numbers
Alumis reported Q3 2026 revenue of $1.9 million, all collaboration revenue tied to its agreement with Kaken Pharmaceutical, against $2.1 million a year earlier. For a pre-commercial company this line is incidental. The story is the cost base.
Operating expenses were $100.98 million, down from $117.36 million in Q3 2025, leaving a loss from operations of $99.08 million versus $115.29 million. Interest income was $4.3 million, against $4.6 million a year earlier. Net loss was $94.9 million, compared with $110.8 million in the prior-year quarter.
Subscribe to keep reading
$4.99 / month
- Every article, analysis and opinion piece on CompePharma and VigiEye
- One subscription for both sites, cancel any time
Already a subscriber? Enter your email below: we'll send you a sign-in link. No password needed.
Sources
- Alumis Inc.: quarterly results release (SEC filing) SEC EDGAR · 12 Nov 2026
Written by CompePharma's editorial system (AI-assisted, model claude-sonnet-5-5) strictly from the official material listed. Earnings analysis is based on the company's results release filed with the SEC, not on the earnings call. It can contain errors; check the sources. Not investment advice.
CorMedix Q3: Post-TDAPA DefenCath Reset Meets Heron Deal and a Suspended 2027 Outlook
Consolidated revenue of $54.5M beat the consensus the company cited, but DefenCath pricing, a $3.1M adjusted EBITDA and suspended 2027 guidance leave Heron and REZZAYO carrying the story.
Iambic's Q3: AI-platform deals double revenue, but the clinic drives the burn
Collaboration revenue rose to $11.4M and pro forma cash reached about $455M after the IPO, while R&D and G&A spending climbed as Iambic moves three oncology assets toward and into the clinic.
Ionis lowers TRYNGOLZA outlook to ~$50M as DAWNZERA and partners carry Q3
Ionis reaffirmed total revenue, operating loss and cash guidance, but cut 2026 TRYNGOLZA sales to about $50 million from $100-110 million as its first large-indication launch ramps more slowly.